Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Haruyasu Murakami
Shizuoka Cancer Center - Division of Thoracic Oncology
Japan
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
157
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Durable Anti-Tumour Activity of the Multi-Targeted Inhibitor Lenvatinib in Patients with Advanced or Metastatic Thymic Carcinoma: A Multicentre Phase II (REMORA) Trial
Number of pages: 52
Posted: 05 Feb 2020
Jun Sato
,
Miyako Satouchi
,
Shoichi Itoh
,
Yusuke Okuma
,
Seiji Niho
,
Hidenori Mizugaki
, Haruyasu Murakami,
Yasuhito Fujisaka
,
Toshiyuki Kozuki
,
Kenichi Nakamura
,
Yukari Nagasaka
,
Mamiko Kawasaki
,
Tomoaki Yamada
,
Ryunosuke Machida
,
Aya Kuchiba
,
Yuichiro Ohe
and
Noboru Yamamoto
National Cancer Center Hospital - Department of Experimental Therapeutics, Hyogo Cancer Center, Hyogo Cancer Center, Komagome Hospital - Tokyo Metropolitan Cancer and Infectious Diseases Center, National Cancer Center Hospital East, Hokkaido University, Shizuoka Cancer Center - Division of Thoracic Oncology, Osaka Medical College, National Hospital Organization Shikoku Cancer Center, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital and National Cancer Center Hospital - Department of Experimental Therapeutics
Downloads
157
(474,889)
View PDF
Download
Abstract:
Lenvatinib; thymic carcinoma; phase II; multi-targeted inhibitor
Feedback
